2-{6-[6-azaspiro[2.5]oct-6-yl(4-fluorophenyl)methyl]-4'-(trifluoromethyl)biphenyl-3-yl}propanoic acid | 1257396-70-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 2-{6-[6-azaspiro[2.5]oct-6-yl(4-fluorophenyl)methyl]-4'-(trifluoromethyl)biphenyl-3-yl}propanoic acid
• 英文别名: 2-[4-[6-Azaspiro[2.5]octan-6-yl-(4-fluorophenyl)methyl]-3-[4-(trifluoromethyl)phenyl]phenyl]propanoic acid；2-[4-[6-azaspiro[2.5]octan-6-yl-(4-fluorophenyl)methyl]-3-[4-(trifluoromethyl)phenyl]phenyl]propanoic acid
• CAS: 1257396-70-5
• 化学式: C₃₀H₂₉F₄NO₂
• 分子量: 511.559
• InChiKey: HUWMZFCDEGMPHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  6-氮杂螺[2.5]辛烷 在 吡啶 、 四(三苯基膦)钯 、 水 、 sodium carbonate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 甲苯 、 2,3,4-三氟甲苯 为溶剂， 生成 2-{6-[6-azaspiro[2.5]oct-6-yl(4-fluorophenyl)methyl]-4'-(trifluoromethyl)biphenyl-3-yl}propanoic acid
  参考文献：
  名称：

  Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator

  摘要：

  We have investigated a novel series of acid-derived gamma-secretase modulators as a potential treatment of Alzheimer's disease. Optimization based on cellular potency and brain pharmacodynamics after oral dosing led to the discovery of 10a (BIIB042). Compound 10a is a potent gamma-secretase modulator, which lowered A beta 42, increased A beta 38, but had little to no effect on A beta 40 levels both in vitro and in vivo. In addition, compound 10a did not affect Notch signaling in our in vitro assessment. Compound 10a demonstrated excellent pharmacokinetic parameters in multiple species. Oral administration of 10a significantly reduced brain A beta 42 levels in CF-1 mice and Fischer rats, as well as plasma A beta 42 levels in cynomolgus monkeys. Compound 10a was selected as a candidate for preclinical safety evaluation.

  DOI：

  10.1021/ml200175q

文献信息

• Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator
  作者：Hairuo Peng、Tina Talreja、Zhili Xin、J. Hernan Cuervo、Gnanasambandam Kumaravel、Michael J. Humora、Lin Xu、Ellen Rohde、Lawrence Gan、Mi-young Jung、Melanie N. Shackett、Sowmya Chollate、Anthone W. Dunah、Pamela A. Snodgrass-belt、H. Moore Arnold、Arthur G. Taveras、Kenneth J. Rhodes、Robert H. Scannevin

  DOI：10.1021/ml200175q

  日期：2011.10.13

  We have investigated a novel series of acid-derived gamma-secretase modulators as a potential treatment of Alzheimer's disease. Optimization based on cellular potency and brain pharmacodynamics after oral dosing led to the discovery of 10a (BIIB042). Compound 10a is a potent gamma-secretase modulator, which lowered A beta 42, increased A beta 38, but had little to no effect on A beta 40 levels both in vitro and in vivo. In addition, compound 10a did not affect Notch signaling in our in vitro assessment. Compound 10a demonstrated excellent pharmacokinetic parameters in multiple species. Oral administration of 10a significantly reduced brain A beta 42 levels in CF-1 mice and Fischer rats, as well as plasma A beta 42 levels in cynomolgus monkeys. Compound 10a was selected as a candidate for preclinical safety evaluation.